13F Holdings
中文EN

IMCR Immunocore Holdings plc

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1671927 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY13.1%
TTM net income YoY-9.9%
TTM EPS YoY-10.3%
Revenue 3-yr CAGR25.9%
Net income 3-yr CAGR—

Margins

Gross margin98.9%
Operating margin-6.8%
Net margin-7.5%
FCF margin-4.2%
EBITDA margin-5.9%

Returns

ROE-7.9%
ROA-2.9%
ROIC (approx.)—
Asset turnover0.38x

Leverage & solvency

Liabilities / assets62.8%
Debt / equity0.00x
Current ratio4.62x
Interest coverage-2.37x

Cash quality & payout

Operating cash flow / net income0.32x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue1.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31 · USDFY20242024-12-31 · USDFY20232023-12-31 · USDFY20222022-12-31 · GBPFY20212021-12-31 · GBP
Income statement
Revenue$400.02M$310.20M$249.43M143.74M26.52M
Cost of revenue$5.09M$2.73M$1.04M454,0000
Gross profit$394.93M$307.47M$248.39M143.28M26.52M
R&D expense$274.87M$222.15M$163.54M89.17M73.23M
SG&A expense$165.41M$155.78M$144.50M93.72M88.40M
Operating income-$45.35M-$70.46M-$59.65M-39.61M-135.16M
Interest expense$12.17M$18.84M$5.15M7.69M5.81M
Pretax income-$19.10M-$52.94M-$60.89M-44.15M-140.93M
Income tax$16.41M-$1.85M-$5.60M-2.92M-9.40M
Net income-$35.51M-$51.09M-$55.29M-$52.54MUSD-$180.03MUSD
EBITDA-$42.25M-$66.26M-$55.55M——
EPS (basic)-0.71-1.02-1.13-0.90-3.10
EPS (diluted)-0.71-1.02-1.13-0.90-3.10
Dividends declared per share0.000.000.000.00USD—
Weighted avg. shares (diluted)50.35M49.99M48.89M45.71M42.49M
Balance sheet
Cash & equivalents$467.71M$455.73M$442.63M332.54M237.89M
Short-term investments$396.44M$364.64M$0——
Receivables—$63.01M$52.09M46.71M15.21M
Inventory$6.74M$5.45M$4.50M943,0000
Current assets$996.74M$929.86M$528.82M391.88M262.73M
PP&E, net$11.46M$10.09M$9.21M6.47M8.94M
Total assets$1.07B$1.01B$597.00M435.52M301.77M
Current liabilities$246.70M$212.18M$139.02M83.09M61.18M
Short-term debt———0—
Long-term debt———39.50M37.23M
Total debt———39.50M37.23M
Total liabilities$686.24M$648.79M$228.16M156.76M130.23M
Shareholders' equity$381.03M$360.72M$368.84M$338.90MUSD$233.71MUSD
Net debt———-293.04M-200.66M
Shares outstanding50.69M50.06M49.73M48.09M212,238
Cash flow statement
Operating cash flow-$10.71M$26.06M$2.94M-25.89M-96.11M
Capital expenditure$4.34M$5.17M$5.42M1.79M1.01M
Free cash flow-$15.05M$20.89M-$2.48M-27.68M-97.12M
Investing cash flow-$16.34M-$355.13M-$5.42M193,000-367,000
Financing cash flow$12.37M$343.88M$34.35M114.45M204.63M
Depreciation & amortization$3.10M$4.20M$4.10M$5.30MUSD$7.60MUSD
Stock-based compensation$37.70M$34.19M$32.47M27.05M35.86M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company uses different currencies across periods or line items (e.g. USD convenience translations in annual reports). Each column header shows its currency and cells in a different currency are marked; do not compare figures across currencies. Charts use only periods in the latest period's currency.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.